Platelet Drug Trial in Coronary Disease Progression

• Status: Completed
• Trial end date: 1982-12-01
• Target enrollment: 0
• Participant gender: All

Summary

To determine the effectiveness of the platelet inhibitor drugs dipyridamole and aspirin in reducing the angiographic progression of coronary artery disease over a five-year period and to test the predictive value of the platelet survival half-life in identifying patients with more rapid progression of coronary disease and development of its complications.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
• Treatments: Aspirin; Dipyridamole

Criteria

Patients aged 65 or less. Angiographically identified coronary heart disease